Can we counterbalance restricted access to innovation through specialized breast cancer care? The REAL-NOTE study
Notwithstanding the study limitations, outcomes of patients treated with chemotherapy without immunotherapy were numerically similar to the experimental arm of KN-522 trial. These data highlight that providing care by a specialized multidisciplinary team in a certified unit might be just as impactful as the incorporation of new technologies.
Authors
- Berta Sousa (ORCID: https://orcid.org/0000-0003-2287-4799)
- Fátima Cardoso (ORCID: https://orcid.org/0000-0002-6692-2249)
- Leonor Vasconcelos de Matos (ORCID: https://orcid.org/0000-0001-9568-238X)
- Márcio Debiasi (ORCID: https://orcid.org/0000-0002-7265-7533)
- Teresa Padrão (ORCID: https://orcid.org/0000-0002-4199-7252)
Institutions
- Champalimaud Foundation (PT)
Publication Details
- Journal
- The Breast
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1016/j.breast.2024.103793
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00